MeridianConsensus
Decision-grade Market IntelligenceAny market · any geography
Meridian Consensus is a market intelligence platform built around one proposition: every published figure clears a five-stage research process and adversarial committee sign-off. The platform, the framework, and the research leadership are documented below.
The platform at a glance
Thirteen catalogued verticals. Unlimited commissioned scope.
Framing · Evidence Assembly · Triangulation · Stress-Test · Committee.
Independent sign-off required before publication. No exceptions.
Plus event-triggered revisions. Every diff disclosed against the prior thesis.
Unlimited written Q&A with the Senior Analyst. No voice calls.
Confirmed errors are fixed in place with a correction note.
Firm positioning
Decision-grade market research has historically been sold on an access window measured in weeks. The six-to-twelve-week waiting period was a structural artefact of distributed research teams, manual data collection, and typeset publication, a cost of operation, not a quality signal.
The Meridian Consensus Framework was designed around the observation that the waiting period is no longer load-bearing. The methodology that produces a decision-grade market study, evidence assembly, triangulation, stress-testing, committee review, runs on a pipeline architecture that compresses the calendar while preserving every substantive quality gate. Figures clear the same framework. Readers simply receive the output on demand.
Where traditional syndicated research costs $2,500 to $5,000 per report with six-to-twelve-week access windows, Meridian delivers equivalent depth instantly on demand for $799. Every figure traces back to its evidence path. Every report is signed off by an adversarial research committee. Every correction is dated and disclosed in place. Transparency, cadence, and price are positioned as deliberate choices rather than inherited constraints.
Research principles
Every figure on our platform is reconstructed from at least three independent evidence paths. Nothing publishes on the strength of a single source or the authority of the author.
An adversarial research committee independent of the authoring analyst reviews every report. No committee sign-off, no publication.
When we get something wrong, we fix it in place, date the correction, and surface the diff. Quiet edits are a governance failure, not a convenience.
Where the evidence supports a point estimate, we publish one. Where it supports a band, we publish a band. We do not hide uncertainty behind the third decimal place.
Client practice areas
Meridian reports are produced to a standard that clears an investment committee, a board paper, a Tier-1 consulting partner review, and a sell-side coverage note, without rework.
M&A target screening, opportunity-landscape sizing, and committee briefing papers. Where the investment committee needs an institutional point estimate, not a research summary.
Diligence-grade sizing, competitive-share reconciliation, and operator-interview-backed thesis validation on thesis-stage and bolt-on opportunities.
Portfolio-company market context, TAM/SAM/SOM reconstruction for board papers, and sector pattern-recognition memos across the fund investment thesis.
White-label commissioned studies that pass a Tier-1 partner review. Accessed in days, not eight weeks, without the consulting firm's own access overhead.
Pre-computed sector-consensus figures for coverage notes, with variance explicitly disclosed rather than averaged away. Citable, audit-trailed, defensible under IC.
Market-entry scoping, pricing benchmarks, and competitive-landscape maps for product, strategy, and GTM teams. The institutional-grade read without the institutional-grade price.
Research leadership
Editorial desk
Research Committee
Chief Research Office
The research committee architected the Meridian Consensus Framework, the proprietary five-stage research process that underpins every figure on the platform, and reviews every published report. The committee focuses on making investment-grade market intelligence accessible to the operators, founders, and investors who need defensible numbers without the six-figure research budgets historically required.
Responsible for research standards, methodology, and every figure published under the Meridian Consensus name. Author of the Meridian disclosure framework and the named editor on every preview and full commissioned report.
Every market sits with a domain desk. Desks own methodology specifics for their vertical, what to triangulate against, which sources lead, which signals matter.
Pharma, medical devices, hospital services, clinical pipelines.
Lead: Meridian Consensus Team
EVs, batteries, components, charging, autonomy.
Lead: Meridian Consensus Team
Semiconductors, AI infrastructure, SaaS, data platforms.
Lead: Meridian Consensus Team
Renewables, grid, storage, hydrogen, upstream oil & gas.
Lead: Meridian Consensus Team
Manufacturing, robotics, advanced materials, logistics.
Lead: Meridian Consensus Team
Retail, CPG, e-commerce, direct-to-consumer.
Lead: Meridian Consensus Team
Defense, commercial aviation, space, UAS.
Lead: Meridian Consensus Team
Ag-tech, biotech seeds, food systems, precision ag.
Lead: Meridian Consensus Team
No research firm publishes this. We do. Every material correction is dated, attributed to the validation method that caught it, and linked back to the market page. Inverts the usual trust game: admitting corrections raises accuracy, not lowers it.
| Date | Severity | Market | What we reported | What we corrected it to | Caught by |
|---|---|---|---|---|---|
| 2026-04-18 | Material | Electric Vehicle Battery Market | Reported 2025 CATL share at 36.1% in v3 edition. | Revised to 34.2% after reconciling the CATL FY2024 10-K against CnEVData production volumes. | Bottom-up revenue × capacity-weighted cross-check |
| 2026-03-27 | Material | Interventional Cardiology Market | Forecast CAGR (2025–2035) listed at 8.4%. | Revised to 7.1% after Q4 FDA clearance data for DES-2 coronary stents reset device-cycle assumptions. | FDA 510(k) direction signal + segment-consistency check |
| 2026-03-09 | Clerical | Inpatient Services Market | HCA Healthcare HQ attributed to Tennessee, US. | Clerical, HCA HQ confirmed as Nashville, TN. No numeric impact. | Source-verification pass (manual) |
| 2026-02-21 | Material | Preventive Medicine Market | Regional split listed APAC at 31% share. | Revised to 28.4% after including Japan-specific wellness spending (previously reported under Healthcare IT). | Segment overlap detection (method #10) |
| 2026-02-02 | Minor | (Cross-catalog) | Spelling inconsistency, "MarketsandMarkets" rendered as "Markets and Markets" in 14 sources-cited blocks. | Normalized site-wide. | Linter pass |
Business details
Strategic Intelligence platform
New product surfaces
Attachable Layers append dedicated chapters to any report (from $79, free quota per plan). Intel Watchlists run an ongoing industry feed for Senior Analyst Support subscribers (M&A, exec moves, regulatory dockets, patent filings) delivered weekly or daily.
